Menactra Disease Interactions
There are 3 disease interactions with Menactra (meningococcal conjugate vaccine).
Meningococcal conjugate vaccine (applies to Menactra) GBS
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Guillain-Barre Syndrome
Persons previously diagnosed with Guillain-Barre syndrome (GBS) may be at increased risk of GBS following receipt of meningococcal conjugate vaccine. The decision to give this vaccine should take into account the potential benefits and risks.
Vaccines (applies to Menactra) IM injection
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thrombocytopenia, Thrombocytopathy, Coagulation Defect
In patients with thrombocytopenia or coagulation disorders, IM injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine; hepatitis A and B vaccines; aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered IM. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.
Vaccines (live attenuated/toxoid) (applies to Menactra) immunocompromised
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency
The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.
Switch to professional interaction data
Menactra drug interactions
There are 302 drug interactions with Menactra (meningococcal conjugate vaccine).
Report options
More about Menactra (meningococcal conjugate vaccine)
- Menactra consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bacterial vaccines
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Cipro
Cipro (ciprofloxacin) is a fluoroquinolone antibiotic used to treat bacterial infections. Learn ...
Rocephin
Rocephin (ceftriaxone) is used to treat bacterial infections, including severe or life-threatening ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Menveo
Menveo (meningococcal conjugate vaccine) is used to prevent infection caused by meningococcal ...
Rifadin
Rifadin is used for bartonellosis, endocarditis, haemophilus influenzae prophylaxis, legionella ...
Trumenba
Trumenba is used for meningitis, meningococcal, meningococcal disease prophylaxis
Bexsero
Bexsero is used for meningitis, meningococcal, meningococcal disease prophylaxis
Meningococcal polysaccharide vaccine
Meningococcal polysaccharide vaccine is used for meningococcal disease prophylaxis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.